Your session is about to expire
← Back to Search
Tirzepatide for Obesity (SURMOUNT-3 Trial)
SURMOUNT-3 Trial Summary
This trial will study the effects of tirzepatide in obese people. It will last 29 visits and span 2 years, in order to see if tirzepatide can help with weight loss or maintenance.
- Obesity
SURMOUNT-3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSURMOUNT-3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 210 Patients • NCT05024032SURMOUNT-3 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA cleared Tirzepatide for public consumption?
"There is available clinical data that supports the efficacy of Tirzepatide, making it a safe medication with a score of 3."
To your knowledge, has a study like this been conducted before?
"Tirzepatide has been under scientific study since 2019 when it was first developed by Eli Lilly and Company. After the initial Phase 1 study on 196 individuals, Tirzepatide received approval for Phase 2 testing. As of now, there are 10 ongoing studies involving Tirzepatide in 621 locations across 31 countries."
Are there other examples of Tirzepatide's effectiveness?
"Tirzepatide was first studied in 2019 by American Research Corporation at Texas Liver Institute. Following that, there have been 18302 completed clinical trials. Right now, 10 clinical trials are actively recruiting patients with a significant portion of these studies based out of Pittsburgh, Pennsylvania."
What are the benefits that researchers hope to gain from this clinical trial?
"This clinical trial will last for approximately 72 weeks and its primary goal is to track the percent change in body weight of participants. Additionally, the study hopes to understand how effective the intervention is by measuring the percentage of patients who achieve a ≥15% reduction in body weight, changes in physical function (as measured by the Short Form 36 Version 2 Health Survey), and changes in waist circumference."
Are there more than one location where this research project is taking place within the state?
"44 clinical trial sites are actively recruiting patients for this study, which includes locations in Pittsburgh, Dallas and Muncie. To reduce travel burden, please select the location nearest to you when enrolling."
How many test subjects are required for this experiment?
"Unfortunately, this study has already closed recruitment. However, there are presently 1191 clinical trials actively admitting patients with obesity and 10 trials for Tirzepatide actively enrolling participants."
Are there still positions available for volunteers in this research project?
"Information available on clinicaltrials.gov suggests that this particular study is not presently looking for patients to enroll. Although the trial's last update was on March 22nd, 2022, it is one of 1201 other trials recruiting subjects as we speak."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Cleveland Clinic Foundation: < 24 hours
- National Research Institute (NRI) - Santa Ana: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger